Basic Information
| LncRNA/CircRNA Name | FGF14-AS2 |
| Synonyms | FGF14-AS2 |
| Region | GRCh38_13:102394630-102395703 |
| Ensemble | ENSG00000272143 |
| Refseq | NR_036487 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, RIP etc. |
| Sample | breast cancer tissues |
| Expression Pattern | down-regulated |
| Function Description | In this study, we demonstrated that FGF14 antisense RNA 2 (FGF14-AS2), a novel long non-coding RNA, was significantly down-regulated in breast cancer tissue compared with adjacent normal tissue both in validated cohort and TCGA cohort. Reduced expression of FGF14-AS2 was correlated with larger tumor size, more lymph node metastasis and advanced clinical stage in both cohorts. |
| Pubmed ID | 26820525 |
| Year | 2016 |
| Title | A novel long non-coding RNA FGF14-AS2 is correlated with progression and prognosis in breast cancer. |
External Links
| Links for FGF14-AS2 | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |